- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03023566
Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI
Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI in Pediatric and Neonatal Patient Population (<18years)
Study Overview
Detailed Description
Phoenix Children's Hospital (PCH) performs approximately 200 contrast enhanced MRI procedures per month. Recently PCH changed its MRI contrast agent from the linear contrast agent Magnevist to the macrocyclic contrast agent Dotarem. The goal of this study is to evaluate safety and efficacy of Dotarem enhanced MRI in pediatric and neonatal population who are referred for contrast enhanced MRI at PCH.
The study is designed as a single center, open label comparison of unenhanced MRI with Dotarem enhanced MRI in pediatric patient population (<18years). The comparison will be performed intra-individually by 3 independent blinded radiologists. Overall, the study population will consist of 250 pediatric patients who are indicated for contrast enhanced MRI. The safety follow-up period will be 24 (+/- 4) hours post injection of Dotarem and includes the assessment of physical examinations and vital signs as well as the assessment of AEs.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Phoenix Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any patient under 18 years of age who is scheduled for contrast enhanced MRI examination as part of their standard of care.
- Patients who are willing to undergo contrast enhanced MRI procedure
- Patients who are willing to comply with the study procedures (e.g. being followed-up for 24 hours after MRI procedure).
- Patients who have given their fully informed and written consent voluntarily.
Exclusion Criteria:
- Patients receiving an MRI exam without contrast.
- Patients who are pregnant, lactating or who are > 11 years old and have not had a negative urine pregnancy test the same day as administration of Dotarem. The manufacturer's instructions for performing the urinary pregnancy test are to be followed.
- Having an underlying disease or concomitant medication which may interfere with efficacy or safety evaluations as planned in this study.
- Patients with a Glomerular Filtration Rate (GFR) < 30.
- Having received any investigational drug within 30 days prior to entering this study or who are planned to receive any investigational drug during the 24 (+ / - 4) hour safety follow-up period.
- Not being able to remain lying down for at least 45 - 60 min (e.g. patients with unstable angina, dyspnea at rest, severe pain at rest, severe back pain).
- Presenting with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents .
- Patients who have received any other contrast medium within 24 hours prior to Dotarem injection or are scheduled to receive any other contrast medium within the follow-up period.
- Being clinically unstable and whose clinical course during the 24 (+ / - 4) hours observation period is unpredictable.
- Being scheduled for, or likely to require, any surgical intervention within 24 hours before or within the follow-up period.
- Having any contraindication to MRI examination (e.g. pacemaker, recent wound clips, and severe claustrophobia).
- Having been previously enrolled in this study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Dotarem Enhanced MRI
All pediatric patients (< 18 years) scheduled for clinically indicated contrast enhanced MRI (Brain MRI with/without contrast) will receive a single IV bolus injection of Dotarem at a dose of 0.1 mmol/kg bw at a flow rate of 1-2 mL/sec followed by saline flush (routine/ standard of care).
|
Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall lesion visualization and characterization
Time Frame: 24 - 48 hours
|
Overall lesion visualization and characterization, based on assessment of (1) lesion border delineation, (2) internal morphology and (3) degree of contrast enhancement.
All images from "Pre" (unenhanced MRI) and "Paired" (unenhanced + enhanced) MRI will be evaluated independently by the 3 independent readers and are rated on a 3-point scale as unevaluable (0), seen but imperfectly (1) or seen completely/perfectly (2).
The primary statistical analysis compared unenhanced MRI to combined MRI.
The efficacy of Dotarem is expected to be demonstrated for at least 2 out of 3 readers independently meeting a statistically significant positive difference between the mean "Paired" score and the mean "Pre" score at patient level for each co primary endpoints.
|
24 - 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of enhanced MRI compared to unenhanced MRI
Time Frame: 24 - 48 hours
|
Efficacy of enhanced MRI compared to unenhanced MRI, based on (1) lesion counting, (2) signal intensity measurements, (3) image quality evaluation, and (4) diagnostic confidence (defined on 1-5 scale; 1= no confidence and 5 represents very high confidence
|
24 - 48 hours
|
Assessment of adverse events (AEs)
Time Frame: 24 hours (+ / - 4 hours)
|
Assessment of adverse events (AEs), volunteered, observed or elicited by vital signs, physical examination, and continuous monitoring of AEs from the beginning of Dotarem injection until end of the follow-up period of 24 (+ / - 4) hours after contrast administration.
|
24 hours (+ / - 4 hours)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeffrey H Miller, MD, Phoenix Children's Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCH IRB#16-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Diseases
-
Brent MaselThe Moody FoundationCompletedChronic Traumatic Brain InjuryUnited States
-
Center for Vision Development, New Market, MarylandUnknownBrain Injuries | Brain Injuries, Traumatic | Traumatic Brain Injury | Brain Injury, Chronic | Injury, Brain, TraumaticUnited States
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Oculogica, Inc.CompletedMild Traumatic Brain Injury | Concussion, BrainUnited States
-
Oculogica, Inc.Completed
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...Enrolling by invitationMild Traumatic Brain Injury | Concussion, BrainUnited States
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
University of AarhusAarhus University Hospital; Central Denmark RegionCompletedTraumatic Brain INjuryDenmark
-
Adel HelmyCambridge University Hospitals NHS Foundation TrustUnknownTraumatic Brain INjuryUnited Kingdom
Clinical Trials on Dotarem
-
Vanderbilt University Medical CenterChildren's Hospital of Philadelphia; GuerbetCompletedMagnetic Resonance Imaging Contrast AgentsUnited States
-
Northwestern UniversityCompletedVascular DiseasesUnited States
-
Bracco Diagnostics, IncCompleted
-
BayerCompletedNeoplastic CNS LesionsItaly
-
University of ChicagoGuerbetCompletedBreast Cancer | Breast Neoplasms | Breast Diseases | Breast FibroadenomaUnited States
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico
-
Massachusetts General HospitalWithdrawnContrast Media AllergyUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
Massachusetts General HospitalWithdrawn
-
GuerbetCompletedPeripheral Arterial DiseaseFrance